NI201000072A - Derivados 1, 2, 4 - triazol amino como moduladores de mglur5. - Google Patents

Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.

Info

Publication number
NI201000072A
NI201000072A NI201000072A NI201000072A NI201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A
Authority
NI
Nicaragua
Prior art keywords
modulators
compounds
mglur5
derivatives
amino
Prior art date
Application number
NI201000072A
Other languages
English (en)
Inventor
Isaac Methvin
Wallberg Andreas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201000072A publication Critical patent/NI201000072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con novedosos compuestos amino triazol 1,2,4 el método para su preparación, composiciones farmacéuticas conteniendo dichos compuestos y su uso en terapia. Los compuestos actuan como moduladores de receptores de glutamato metabotrópicos(mGluR) y son en consecuencia útiles en el tratamiento de las relaciones transitorias del esfinter esofágico inferior, la enfermedad de reflujo gastroesofágico, dolor, ansiedad y síndrome del intestino irritable.
NI201000072A 2007-10-26 2010-04-26 Derivados 1, 2, 4 - triazol amino como moduladores de mglur5. NI201000072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98295607P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
NI201000072A true NI201000072A (es) 2011-03-24

Family

ID=40579779

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000072A NI201000072A (es) 2007-10-26 2010-04-26 Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.

Country Status (21)

Country Link
US (1) US20090111821A1 (es)
EP (1) EP2212316A4 (es)
JP (1) JP2011500798A (es)
KR (1) KR20100089091A (es)
CN (1) CN101918399A (es)
AR (1) AR069030A1 (es)
AU (1) AU2008317544A1 (es)
BR (1) BRPI0818679A2 (es)
CA (1) CA2702974A1 (es)
CL (1) CL2008003182A1 (es)
CR (1) CR11391A (es)
DO (1) DOP2010000124A (es)
EA (1) EA201000656A1 (es)
IL (1) IL205289A0 (es)
MX (1) MX2010004362A (es)
NI (1) NI201000072A (es)
PE (1) PE20091348A1 (es)
TW (1) TW200922585A (es)
UY (1) UY31427A1 (es)
WO (1) WO2009054794A1 (es)
ZA (1) ZA201002854B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438052A1 (en) * 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors
RU2013128448A (ru) 2010-12-08 2015-01-20 Осло Юниверсити Хоспитал Хф Производные триазола в качестве ингибиторов сигнального пути wnt
RU2495687C1 (ru) * 2012-06-19 2013-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ лечения больных гастроэзофагеальной рефлюксной болезнью
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
US9745308B2 (en) 2014-09-12 2017-08-29 Chiesi Farmaceutici S.P.A. Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420355D0 (en) * 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
CA2230448A1 (en) * 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
BRPI0507498A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
RU2006127575A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
MX2008012031A (es) * 2006-03-24 2008-10-02 Eisai R&D Man Co Ltd Derivado de triazolona.
TW200811156A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
TW200811137A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators II
TW200808777A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGLUR5 modulators III
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
AU2008340113B2 (en) * 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
WO2009124903A1 (en) * 2008-04-10 2009-10-15 Basf Se Substituted pyridazinylmethyl sulfonamides

Also Published As

Publication number Publication date
WO2009054794A1 (en) 2009-04-30
US20090111821A1 (en) 2009-04-30
CN101918399A (zh) 2010-12-15
PE20091348A1 (es) 2009-10-04
BRPI0818679A2 (pt) 2015-04-14
DOP2010000124A (es) 2010-10-15
MX2010004362A (es) 2010-04-30
KR20100089091A (ko) 2010-08-11
CR11391A (es) 2010-08-05
AU2008317544A1 (en) 2009-04-30
IL205289A0 (en) 2010-12-30
TW200922585A (en) 2009-06-01
CL2008003182A1 (es) 2009-11-27
AR069030A1 (es) 2009-12-23
EP2212316A4 (en) 2012-06-27
JP2011500798A (ja) 2011-01-06
UY31427A1 (es) 2009-05-29
ZA201002854B (en) 2011-10-26
EP2212316A1 (en) 2010-08-04
EA201000656A1 (ru) 2010-12-30
CA2702974A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
NI201000072A (es) Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.
CO6561821A2 (es) Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms
SV2008001369A (es) Benzimidazoles
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
CY1112232T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
HN2010000432A (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
CL2008003811A1 (es) Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
CY1118314T1 (el) Συνδυασμοι αγωνιστων υποδοχεα σεροτονινης για την αγωγη κινητικων διαταραχων
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
ATE473973T1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
EA200800421A1 (ru) Соединения
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"